TriSalus Life Sciences (TLSI) Equity Average (2021 - 2026)

TriSalus Life Sciences (TLSI) has 6 years of Equity Average data on file, last reported at -$10.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 65.06% year-over-year to -$10.5 million; the trailing twelve-month figure through Mar 2026 stood at -$10.5 million (up 65.06% YoY), and the FY2025 full-year result was -$29.9 million, down 12.83% from the prior year.
• Equity Average for Q1 2026 stood at -$10.5 million, up from -$30.3 million in the prior quarter.
• Across five years, Equity Average topped out at -$9.4 million in Q4 2023 and bottomed at -$191.5 million in Q2 2023.
• The 5-year median for Equity Average is -$30.6 million (2024), against an average of -$76.3 million.
• The widest annual swing landed in 2022, when Equity Average plunged 629.81%; it then soared 94.33% in 2023.
• A 5-year view of Equity Average shows it stood at -$165.5 million in 2022, then jumped by 94.33% to -$9.4 million in 2023, then tumbled by 146.78% to -$23.2 million in 2024, then slumped by 30.78% to -$30.3 million in 2025, then surged by 65.25% to -$10.5 million in 2026.
• The last three Equity Average figures came in at -$10.5 million (Q1 2026), -$30.3 million (Q4 2025), and -$23.1 million (Q3 2025), per Business Quant data.

Peer Comparison